laboratori corp america hold lh nyse qqqq
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
particip highli attract duopoli offer bright
prospect healthcar move toward reform payment model
even though hospit still domin billion diagnost
market labcorp carv signific slice pie
serial acquisit addit covanc drug-develop
expertis offer labcorp avenu monet larg patient
importantli labcorp single-mindedli pursu greater
effici translat abil reduc cost
quickli reimburs cut come pike firm
invest greater autom system decreas
number employe involv sort run test
labcorp also put signific resourc behind beef
inform technolog capabl result physician
easili access test inform time manner
patient schedul blood draw increas conveni
admir manag team consist focus
strategi long term expect labcorp
invest today reap reward futur year
labcorp take advantag long-term secular trend
bode well diagnost industri prolifer
new test grow new diseas marker genet mutat
pharmacogenom
implic discov new
reimburs model inspir healthcar reform lead
doctor hospit send test lower-cost produc
pama reimburs pressur medicar remain
strongest near-term headwind though price cut
stabil unlik get significantli wors
think reimburs pressur could eas
hospital-bas lab reimburs higher level
includ recalcul medicar clinic lab fee
schedul question remain whether hospital-bas lab
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
laboratori corpor america one nation two largest
independ clinic laboratori roughli independ lab
offer broad rang clinic lab test rang routin blood
urin screen complex oncolog genom test
addit covanc labcorp also sizabl footprint global
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
slightli rais fair valu estim per
share half increas come slightli
optimist project diagnost busi
remaind time valu money
continu expect robust growth drug
develop busi return
sustain growth addit chiltern give
labcorp greater footprint small medium size
biopharma area assum new medicar clinic lab
fee schedul adjust first three-year cycl
rate set greater impact
eas thank lab act delay
reset rate estim top-lin
growth averag annual oper margin
steadili expand next five year
keep long-term trend anticip
increas growth genom esoter test compar
routin test labcorp done good job
launch new complex test lead us believ
annual esoter test volum outpac market growth
also think special test carri higher
price tag routin counterpart result averag
annual price increas long term
off-set reimburs pressur routin
test still make bulk labcorp test mix
think labcorp invest covanc
allianc larg payer put
firm strong posit take advantag emerg
opportun longer term demonstr
valu refer lab add beyond deliveri reliabl
accur test data anticip acquisit add
approxim per year total revenu growth
base averag volatil cash flow labcorp
underli diagnost busi would rate firm
uncertainti medium
bull case valu share scenario
assum robust volum gain better-than-expect
cost contain effici follow increas
thank hospital-bas lab compli
growth covanc clinic trial busi result
adjust annual top-lin growth
higher throughput assum labcorp enjoy greater
oper leverag translat
gain oper margin tp sale
bearish scenario project sluggish volum growth
number uninsur patient rise second
trump term on-going albeit gradual cut medicar
reimburs drug develop segment
fail reach histor growth level estim
oper margin eke basi point next
five year due weak volum tight price pressur
case put fair valu estim per share
labcorp narrow moat base vast nation
infrastructur translat consider scale
advantag smaller region lab independ
diagnost test industri primari test lab
patient-servic center across unit state
labcorp abl run test specimen day
substanti lower cost hospit
doctor offic smaller independ lab popul
market labcorp abil accommod higher
throughput extens use autom afford
firm much lower cost structur -- significantli lower
hospit smaller independ lab
advantag also mean labcorp model character
substanti oper leverag oper leverag
work firm wake recess
healthcar util fell howev util
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
final labcorp scale reach make attract
partner research invent variou diagnost test
distribut channel sell
test labcorp recent invest dedic lab
focus companion diagnost anoth indic
firm think creativ
close partner entiti healthcar arena
think addit covanc solidifi labcorp
narrow moat -- previous award covanc narrow
moat right contract research organ
moatiest part busi late-stag clinic
trial global infrastructur critic easili
replic legaci covanc busi also benefit
intang asset includ expertis local countri
cultur regulatori agenc chang regul
research design data analyt knowledg key diseas
state close relationship pharmaceut
biotech client clinic trial busi tap
labcorp enorm patient databas order better
match elig patient appropri trial reduc
enrol time capabl give labcorp advantag
competit
see labcorp moat trend posit think labcorp
particularli well-posit take advantag
long-term opportun emerg wake
healthcar reform evolut volume-bas
value-bas reimburs payer assess valu
link chain patient diagnosi
treatment simultan widespread adopt
new digit tool manipul analyz patient data
two factor set stage diagnost
compani demonstr valu diagnost
test -- specif much time money save --
captur valu tradit gone
therapeut agent end-stag treatment new
avenu growth diagnost compani exist
return growth labcorp also benefit though
addit cro busi pressur margin
although price ration recent past
potenti price competit keep us award
payer would typic rather negoti largest
refer lab includ labcorp provid best
geograph coverag insur base instead
cobbl togeth market-by-market coverag
multipl smaller region local lab departur
exclus agreement use character contract
privat payer
organ begun shift differ model
allow lowest-cost produc labcorp
quest in-network lab think reflect
influenc value-bas healthcar reform becom
econom attract encourag patient use
low-cost produc place expens
hospital-bas lab instead pit labcorp quest
eke save also reduc
patient access lower-cost test
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
patient grow signific proprietari asset
healthcar reform push labcorp
quest new nonexclus contract
latest step closer collabor bring diagnost data
claim data togeth analyt use
see new growth prospect horizon
diagnost compani abil ultim capit
depend well develop capabl beyond
current core compet logist lab qualiti
must develop new expertis data collect
integr well informat point think
labcorp pull ahead quest prepar
first labcorp alreadi laid groundwork
integr inform technolog platform --
first step toward possibl aggreg test data
second labcorp alreadi dip toe water
come informat challeng
measur cost save diagnost particular
think firm experi demonstr result
small-scal kidney stone manag chronic
kidney diseas monitor program give labcorp leg
competit futur expect see labcorp
target key diseas area early-detect
treatment monitor program could implement
provid cost save addit covanc late-stag
trial expertis boost labcorp abil conduct
third acquisit covanc expertis data
analyt clinic trial give labcorp big boost
capabl anticip labcorp find new
applic covanc compet tie diagnost
measur therapi patient outcom cost
expect accumul longitudin data mani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
dissip new
nonexclus relationship help labcorp navig
oif signific number hospital-bas lab ill-
equip compli medicar payment
report requir reimburs pressur
could increas even time frame
oth complex labor-intens esoter test
reimburs higher rate often outsourc
hospit independ lab labcorp funnel
resourc broaden menu complex esoter
test help maintain healthi margin
olabcorp abl keep less profit
capit managed-car contract minimum
account diagnost revenu
olabcorp need analyt expertis covanc
would diminish labcorp retain
oit could take longer anticip bundl
payment becom norm provid
case increas volum ensu oper
leverag could five year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
acquisit covanc increas labcorp debt
leverag substanti fund acquisit earli
labcorp borrow five-year term loan may
prepaid without penalti billion new senior
unsecur note matur
end decemb labcorp debt stood
billion time ebitda time prior
acquisit howev end debt/ebitda
fallen time firm debt tick time
hover around time sinc labcorp
yet reach target ratio time longer
term comparison quest aim low long
run even slightli higher long-term gross leverag
goal labcorp typic oper higher cash level
may keep net leverag roughli line even slightli
lower quest long run addit
million cash held balanc sheet end
estim labcorp abl gener
billion averag annual free cash flow next five
year give firm flexibl
surpris see labcorp refin debt come
due
base averag volatil cash flow labcorp
underli diagnost busi rate firm
uncertainti medium despit mani long-term clinic
undercurr favor labcorp see
potenti near-term bumpi thank pama-rel
reimburs cut public health
measur could damp traffic patient servic center
sever great recess spur declin
patient volum across specialti
consum delay seek healthcar especi
nonacut nonsymptomat condit seen
gradual resumpt growth patient traffic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
drop key measur afford
act dismantl could lead less volum higher
reimburs
penetr high-deduct plan substanti
cost-shar measur also left patient larger
out-of-pocket burden could becom perenni drag
growth diagnost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
repres date owner name posit common share held report holder issuer
assign standard stewardship rate labcorp adam
schechter took ceo late take
david king held posit sinc earli
like schechter come deep healthcar experi
time merck moreov alreadi familiar
labcorp diagnost industri
particip labcorp board director sinc
recogn former ceo king led labcorp
unchart water pursu unorthodox strategi
acquir covanc riski move gener
turn posit perspect nonetheless
long-term opportun potenti
combin busi fall schechter
captur overal think -- thank previou
manag prudenc -- labcorp well posit
adapt potenti move new line busi
especi healthcar system lurch toward
share
fund
main reserv manag
rel gener approach compens king
earn million million
past four year eager see schechter
compens stack
share
fund
overal appreci manag execut
year firm maintain great major
contract payer provid custom even
rack new client sizabl empir
cross shield plan new york importantli
like labcorp capital-alloc decis particular
firm exercis financi disciplin acquisit
strategi acquisit accret shortli
close firm avoid write goodwil
unlik rival quest labcorp embrac model
includ ownership hospital-bas lab asset
think difficult extract much valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
independ lab hospit outreach program although
labcorp pay dividend manag funnel
return sharehold form share buyback
applaud firm acceler repurchas share
trade discount
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
quest labcorp enter test market
chang fair valu estim
infect increas
surpris see diagnost lab giant quest diagnost
labcorp move full steam ahead
laboratory-develop test novel viru labcorp
test avail use doctor order start
yesterday quest start monday march
point increas fair valu estim
compani basi new
test though expect moder increas
valuat labcorp revisit assumpt
clinic trial busi clear test
price consid public health aspect
crisi wouldnt surpris price fall well short
typic price refer lab test detect
season influenza even lower point-
nonetheless quest labcorp swift develop
valid assay underscor
narrow econom moat skeptic multitud
smaller independ region lab abl
develop distribut test nearli
quickli also recogn quest labcorp distribut
infrastructur formid competit advantag
situat firm alreadi work larg
major hospit physician
anticip avail new test help
reliev test bottleneck current exist
center diseas control public laboratori
handl test
havent shift valuat taken
closer look new test might play quest
first blush peg test could boost
fair valu estim enough materi
move valuat start review health
human servic pandem scenario
project base case
eventu infect popul roughli
infect assum half seek outpati care
approxim million patient seek care
assum year older
reflect gener popul though ill
popul could well skew older
test high-risk
popul remain seek care
also assum receiv
diagnost test final assum public lab
handl test quest captur
charg per test test price
set increment cash flow impact would even
thank solid fourth-quart result labcorp slightli
exceed full-year expect bottom line
plan moder rais fair valu estim
adjust better-than-expect cost manag
robust drug develop growth midterm
time valu money remain confid labcorp
narrow econom moat saw evid
fourth quarter firm signific cost advantag
help weather first three-year cycl substanti
pama reimburs cut quarter reimburs
pressur pama translat drag
respect organ revenu growth base
pama impact abl quantifi
hamper labcorp revenu growth basi point
sparrow lab larg region hospital-bas lab
basi point strongli suspect pama effect becom
even sever hospit lab consist
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
labcorp manag
hospit
administr seem increasingli recept
discuss altern lab arrang
labcorp full-year revenu billion hit estim
nearli nose howev slightli led earn
project keep tight rein oper expens
includ lower sg margin
estim manag outlook also
optimist weve said recogn
drug develop segment grow
strength develop right tool abl tap
labcorp massiv store data help
acceler clinic trial enrol think
structur competit advantag labcorp hold
compar contract research organ
except iqvia plan revisit assumpt
labcorp drug develop busi reach even
labcorp post solid third quarter expect mute
diagnost perform oct
gener met expect though manag
suggest mute diagnost perform
drag share howev anticip modestli
bump fair valu estim reflect lower share
count well cash flow realiz sinc last updat
manag narrow outlook
consolid project full year remain within
note anticip declin year diagnost
segment driven pama reimburs pressur loss
exclus turn slightli
less sever origin expect weve cut
project declin diagnost revenu basi
point howev recent end labcorp beacon lb
contract translat addit
headwind may disappoint investor
continu expect temper diagnost growth
relief pama price pressur like wont
implement lab act approv
variou chang manag care contract hit organ
volum growth basi point quarter
like continu hand revenu per
requisit held nice pama slice
posit perform quarterli net book-to-bil
backlog continu steadi growth think data
analysi tool labcorp develop marri
patient databas covanc trial design enrol
framework present differenti servic pharma
biotech client asid rival iqvia
proprietari data tool think give two
competitor leg plain-vanilla contract research
organ simpli dont patient data
scale labcorp iqvia
final longtim ceo david king cusp
step reshuffl
manag rank labcorp whole dont
anticip drastic chang strategi incom
ceo adam schecter though fixtur merck
year schecter also labcorp board
sinc recent took role lead
independ director surmis he familiar
two segment labcorp busi like bring
addit insight cro divis consid histori
drug develop merck addit john ratliff
led turnaround covanc segment
move head diagnost unit
challeng lie
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqqq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
